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ABSTRACT 
The health implications of obesity are myriad and multifaceted. Physiologic 
changes associated with obesity can affect the absorption, distribution, metabolism, and 
excretion of administered drugs, thereby altering their pharmacologic profiles. In 2016, 
the Scientific and Standardization Committee of the International Society on Thrombosis 
and Haemostasis published recommendations regarding the use of direct oral 
anticoagulants (DOACs) in obese patients. This guidance provides uniform 
recommendations for all DOACs, yet data suggest that individual agents may be 
affected to different degrees by obesity. Moreover, there are no recommendations 
currently available to guide DOAC use in bariatric surgery patients, in whom anatomic 
and physiologic changes to the digestive system can influence drug pharmacokinetics. 
Our review of the available literature indicates that the clinical profile of the DOAC 
rivaroxaban is not affected by high weight or bariatric surgery; hence, it does not appear 
that rivaroxaban dosing needs to be altered in these patient populations. 
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INTRODUCTION 
An estimated 13% of the world’s population is currently obese (body mass index 
[BMI] ≥30 kg/m2), and the incidence is increasing along with the associated health and 
economic burden.1 Obesity has multifaceted impacts on approaches to patient health 
and disease management, including selection of anticoagulant therapy. Considered a 
prothrombotic and proinflammatory state,2 obesity is a risk factor for conditions where 
anticoagulant therapy is indicated (eg, hip/knee replacement,3 atrial fibrillation,4 venous 
thromboembolism5). Beyond inducing a prothrombotic state, obesity may influence 
thrombotic risk through its effects on the clinical pharmacology 
(pharmacokinetics/pharmacodynamics) of anticoagulants, potentially leading to either 
undercoagulation or overcoagulation, thereby increasing the risk for thrombotic or 
bleeding events. 
Best practices regarding the use of anticoagulants in obese patients remain to be 
determined. The emergence of direct oral anticoagulants (DOACs) broadens the 
anticoagulant treatment armamentarium, but DOAC use in morbidly obese patients 
(BMI ≥40 kg/m2) has been called into question. In 2016, the Scientific and 
Standardization Committee of the International Society on Thrombosis and 
Haemostasis (ISTH) published a guidance that included a suggestion to not use DOACs 
in patients with a BMI >40 kg/m2 or weight >120 kg due to limited clinical data and 
concerns regarding the potential effects of weight extremes on the pharmacology of 
these agents.6 If DOACs are used in these patients, the ISTH guidance suggests 
monitoring drug-specific peak and trough levels. The ISTH recommendations apply to 
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all DOACs, although evidence suggests that their clinical and pharmacologic profiles 
may not be influenced to the same extent by weight.7 
One consequence of the obesity epidemic is the rapidly growing use of bariatric 
surgery. Bariatric surgery, which involves restricting the functional size of the stomach 
and/or inducing nutrient malabsorption, has shown favorable results for reducing weight 
and can produce improvements in obesity-related co-morbidities.8,9 From a drug-
delivery standpoint, a history of bariatric surgery is worth consideration because the 
accompanying anatomic and physiologic changes10 may affect drug pharmacokinetics, 
thereby potentially influencing efficacy and safety.8,9 Understanding changes in 
response to anticoagulant therapy after bariatric surgery is essential due to the elevated 
thrombotic risk in this patient population.11 Little is known, however, regarding the 
pharmacology of DOACs after bariatric surgery, both in the immediate postoperative 
period and during long-term therapy.  
Rivaroxaban is a DOAC that has been extensively studied in a variety of clinical 
indications, including those with a high likelihood of comorbid obesity. Rivaroxaban has 
also been studied in a small number of healthy subjects both before and following 
bariatric surgery. The purpose of this review is to assess the available evidence for use 
of rivaroxaban in the context of obesity or bariatric surgery by examining the published 
literature for studies that have evaluated the clinical or pharmacologic profile of 
rivaroxaban in these patient populations. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
5 
 
METHODS 
Articles for inclusion in this review were identified from the published literature by 
interrogation of the MEDLINE database and by search of abstracts from relevant 
scientific congresses. Search terms included pharmacokinetics, pharmacodynamics, 
obese, obesity, overweight, body weight, BMI, bariatric surgery, and gastric bypass in 
conjunction with rivaroxaban/BAY 59-7939. In addition, reference lists from included 
publications were used to identify other articles of interest. All publications pertinent to 
the subject matter were included in the manuscript; no exclusions based on study 
criteria or date of publication were applied. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
6 
 
RIVAROXABAN AND OBESITY 
The extent of drug exposure is dependent on its absorption, distribution, 
metabolism, and excretion. There is evidence to suggest that each of these components 
may be influenced by obesity.9 However, whether or not drug exposure is affected to a 
measurable or clinically meaningful degree is agent specific. In the case of rivaroxaban, 
pivotal clinical trials, clinical pharmacology studies, and population models provide 
insights into the impact of obesity on drug exposure. 
 
Pharmacokinetic/Pharmacodynamic Studies 
A clinical pharmacology study was conducted to assess the influence of weight 
extremes on the general safety and pharmacologic profile of rivaroxaban after a single 
10-mg oral dose.12 The study enrolled 48 healthy subjects and compared results in 
subjects in weight categories of ≤50 kg (low weight), 70-80 kg (normal weight), and 
>120 kg (high weight). No differences in safety were observed among weight groups. 
The pharmacokinetic profile of rivaroxaban was comparable in subjects in the normal- 
and high -weight groups (Figure 1),12 and the time course of factor Xa activity inhibition 
by rivaroxaban was largely unaffected by weight (Figure 2).12 The authors concluded 
that the overall limited influence of weight on the pharmacologic profile of rivaroxaban 
(ie, generally <15% change compared with normal weight) makes it unlikely that dose 
adjustment is necessary for patients with weight extremes. This study formed the basis 
for the current rivaroxaban prescribing information, which does not suggest dose 
adjustment based on weight.13 
Insights into the influence of weight on the pharmacology of rivaroxaban in more 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
7 
 
diverse patient populations have been obtained through population modeling conducted 
using data from multiple clinical trials in various indications. Two publications have 
reported on the population pharmacokinetics/pharmacodynamics of rivaroxaban in 
patients who had undergone total hip/knee arthroplasty.14,15 The included studies set a 
lower weight limit (45 kg) but no upper bound. Reported weights of enrolled patients 
ranged from 45 kg to as much as 120 to 125 kg (hip studies) or 173 kg (knee study). 
The only notable effect of weight on rivaroxaban pharmacokinetics was a modest 
influence on volume of distribution. Weight was identified as a covariate that influenced 
rivaroxaban-mediated inhibition of factor Xa activity; however, the magnitude of effect 
was small and not considered to be clinically relevant.15 
Mueck16 subsequently published population pharmacokinetics using data from 
two phase 2 studies of rivaroxaban in the treatment of acute deep vein thrombosis. 
These studies excluded patients weighing <45 kg, but had no upper weight/BMI 
threshold. The only rivaroxaban pharmacokinetic parameter influenced by weight was 
the volume of distribution, the effects on which were moderate and within observed 
interindividual variability. Weight did not have a significant effect on the relationship 
between rivaroxaban pharmacologic parameters. In a more recent population 
pharmacokinetic publication that analyzed data from the ROCKET AF study, lean body 
mass (but not body weight/fat) affected the apparent volume of distribution of 
rivaroxaban.17 The influence of lean body mass on the volume of distribution was 
modest and within the range of interindividual variability. 
Together, these analyses indicate that high weight/BMI does not have a clinically 
meaningful impact on the pharmacology of rivaroxaban. Volume of distribution was the 
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parameter most likely to be influenced by high weight/BMI, although it is important to 
note that this difference was within the observed range of interpatient variability.  
 
Efficacy and Safety 
The efficacy and safety of rivaroxaban have been evaluated in several large trials 
across multiple indications, including prophylaxis in patients undergoing total hip/knee 
arthroplasty, treatment of acute venous thromboembolism and prevention of venous 
thromboembolism recurrence, and stroke prevention in atrial fibrillation. These trials 
included a considerable proportion of patients in high weight/BMI categories (Table 
1),18-21 which allowed for weight/BMI-based subgroup analyses. 
 
Total Hip or Knee Arthroplasty. The RECORD series of pivotal clinical studies evaluated 
venous thromboembolism prevention with rivaroxaban versus enoxaparin in patients 
who had undergone total hip/knee arthroplasty.22-25 Turpie21 published a pooled analysis 
of the 4 RECORD studies that included data from 12,279 patients who received either 
rivaroxaban 10 mg daily or enoxaparin 40 mg once daily (or 30 mg every 12 hours). No 
weight or BMI limits were imposed for study inclusion, resulting in considerable 
representation of patients weighing >90 kg (Table 1).18-21 In the overall cohort, the 
primary efficacy endpoint (composite of symptomatic venous thromboembolism and all-
cause mortality) occurred significantly less frequently among those treated with 
rivaroxaban versus enoxaparin (0.5% and 1.0%, respectively; P=0.001). Reductions in 
the composite primary efficacy endpoint were consistent when analyzed by weight 
subgroup (≤70, >70 to 90, and >90 kg) (Figure 3),21 suggesting that the observed 
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benefits of rivaroxaban may also be applicable to patients with high weight. For the 
overall cohort, the rates of major plus clinically relevant nonmajor bleeding were 
comparable in patients who received rivaroxaban (2.8%) or enoxaparin (2.5%; P = 
0.19). These findings were maintained across weight strata (Figure 4).21 
Friedman et al (2013)26 subsequently published a retrospective analysis of the 
RECORD studies to determine whether complication rates after total hip/knee 
arthroplasty are elevated among patients who are morbidly obese. No increase in the 
incidences of asymptomatic/symptomatic deep vein thrombosis, symptomatic 
pulmonary embolism, any bleeding, or major or clinically relevant nonmajor bleeding 
were observed among patients who were morbidly obese (n=445) relative to patients 
with a BMI <40 kg/m2 (n=11,910). Overall, the totality of evidence indicates that the 
efficacy and safety of rivaroxaban among patients undergoing orthopedic surgery is not 
adversely affected by high weight/obesity. 
 
Stroke Prevention in Atrial Fibrillation. Rivaroxaban was studied for the prevention of 
stroke in patients with nonvalvular atrial fibrillation in the pivotal ROCKET AF clinical 
trial.20 Patients in ROCKET AF (N=14,264) received rivaroxaban 20 mg daily (15 mg 
daily in patients with creatinine clearance of 30-49 mL/min) or adjusted-dose warfarin 
(target International Normalized Ratio [INR], 2.0-3.0). Weight was not a study 
enrollment criterion. More than one-quarter of patients weighed >90 kg at baseline 
(Table 1).18-21 The per-protocol and intention-to-treat analyses demonstrated 
noninferiority of rivaroxaban versus warfarin for the primary endpoint (composite of 
stroke or systemic embolism), with consistently lower event rates in the rivaroxaban 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
10 
 
group. Noninferiority of rivaroxaban was maintained across weight/BMI strata (Figure 
3).20 Interestingly, the lowest event rates were observed in the highest weight/BMI 
categories for both treatment groups. A post hoc analysis of ROCKET AF data found 
that the rates of the primary endpoint were significantly lower in overweight (hazard ratio 
[95% confidence interval (CI)]: 0.79 [0.64-0.98]; P=0.029) and obese patients (0.66 
[0.53-0.84]; P≤0.001) in comparison with normal-weight patients.27  
In the overall ROCKET AF cohort, the rates of major and clinically relevant 
nonmajor bleeding were similar in patients receiving rivaroxaban or warfarin.20 However, 
significantly lower rates of intracranial hemorrhage (0.5% and 0.7% per year; P=0.02) 
and fatal bleeding (0.2% and 0.5% per year; P=0.003) were observed in the rivaroxaban 
group. Safety outcomes in the rivaroxaban and warfarin arms, including rates of major 
and clinically relevant nonmajor bleeding (Figure 4),20 were consistent across 
weight/BMI subgroups. The lack of significant effect of obesity on the efficacy and safety 
of rivaroxaban in the context of stroke prevention in atrial fibrillation suggests that the 
pharmacologic profile of this agent in obese and non-obese subjects is likely similar.  
 
Venous Thromboembolism. Two large, pivotal clinical trials assessed the efficacy and 
safety of rivaroxaban for the treatment of acute symptomatic deep vein thrombosis 
(EINSTEIN-DVT) or pulmonary embolism (EINSTEIN-PE).18,19 In both studies, patients 
were randomly assigned to rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 
mg once daily) or enoxaparin followed by a vitamin K antagonist (VKA) for 3, 6, or 12 
months. An extension study allowed an additional 6 or 12 months of treatment for 
qualifying patients. No limitations were placed on enrollment based on weight/BMI. 
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Across studies and treatment arms, ~14% of patients weighed >100 kg (Table 1).18-21 
For the primary efficacy endpoint, symptomatic recurrent venous thromboembolism, 
rivaroxaban was found to be noninferior to enoxaparin/VKA therapy in EINSTEIN-DVT 
and EINSTEIN-PE. Rates of major and clinically relevant nonmajor bleeding (the 
primary safety endpoint) were equivalent between groups in EINSTEIN-DVT (8.1% for 
both) and slightly lower with rivaroxaban versus enoxaparin/VKA therapy in EINSTEIN-
PE (10.3% and 11.4%, respectively; P=0.23). Results for the primary efficacy and safety 
endpoints were consistent across weight subgroups.  
A recently published post hoc analysis of pooled data from the EINSTEIN-DVT 
and EINSTEIN-PE studies detected no association between weight/BMI and risk of 
recurrent venous thromboembolism, major bleeding, or composite of major bleeding 
and clinically relevant nonmajor bleeding in patients who received rivaroxaban.28 
Hazard ratios for the comparison of rivaroxaban and enoxaparin/VKA therapy were 
consistent across weight/BMI subgroups (Figures 3 and 4).28 
Pivotal randomized controlled trial data, although informative for guiding clinical 
practice, may have limited relevance to real-world patient populations. Data from 
everyday practice are, therefore, valuable in providing a perspective on drug efficacy 
and safety in a more diverse patient population. One such study that evaluated the 
effect of weight extremes on the pharmacokinetics, efficacy, and safety of rivaroxaban 
in the treatment of venous thromboembolism was recently reported.29 In this unselected 
group of 219 patients, rivaroxaban plasma concentrations were comparable between 
patients weighing 50-120 kg (median [95% CI]: 308 [308-381] ng/mL) and those 
weighing more than 120 kg (281 [242-327] ng/mL), but were significantly higher in 
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patients weighing less than 50 kg (460 [380-601] ng/mL; P=0.005 for the comparison 
with the 50-120 kg and >120 kg groups). The rates of recurrent venous 
thromboembolism, major bleeding, and clinically relevant bleeding were similar across 
the weight groups, and higher plasma levels of rivaroxaban in patients weighing <50 kg 
were not associated with increased bleeding or recurrent venous thromboembolism. 
These results further support the observed lack of effect of high weight on the clinical 
profile of rivaroxaban that was observed in clinical trials in patients with venous 
thromboembolism. 
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RIVAROXABAN AND BARIATRIC SURGERY 
The influence of bariatric surgery on drug pharmacology, efficacy, and safety is 
largely unknown, as few studies have examined this question. Theoretically, bariatric 
surgery has potential to influence pharmacokinetics of administered drugs via a 
multitude of mechanisms, including changes in gastric emptying time, decreased small 
intestine transit time, and reduced intestinal surface area.8,9 The net result of anatomic 
and physiologic changes on drug pharmacokinetics is highly dependent on the nature of 
the bariatric surgery, route of drug administration, and characteristics of the individual 
drug.  
There is some precedent for bariatric surgery influencing the pharmacology and 
clinical profile of anticoagulants. Vitamin K deficiency has been reported after gastric 
bypass surgery,30 which may significantly impact the anticoagulant effects of VKA 
agents such as warfarin. Functional consequences in terms of poor INR control and 
resulting clinical complications have been observed with VKA use after gastric 
bypass.31-36  
Initial data on the pharmacology of rivaroxaban in patients who had undergone 
bariatric surgery were reported in case studies. Mahlmann et al34 described a patient 
who experienced unstable INR during VKA therapy after undergoing gastric bypass. 
The patient was considered to be at high risk for venous thromboembolism due to prior 
events and, therefore, required continued anticoagulation. After switching to rivaroxaban 
20 mg once daily, plasma drug concentrations, INR, and activated partial 
thromboplastin time were measured. Following the first rivaroxaban dose, plasma drug 
concentrations increased rapidly, reaching peak values that were within the expected 
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range. The authors concluded that “resorption of rivaroxaban is not significantly 
impaired by bariatric surgery.” Similar results were reported by Cintineo37 for a patient 
with atrial fibrillation and history of gastric bypass who experienced a transient ischemic 
attack 3 years after surgery and was subsequently put on rivaroxaban 20 mg daily.  
New data provide insights on the pharmacology of rivaroxaban in the immediate 
postoperative period. A single-center clinical trial evaluated pharmacokinetics of 
rivaroxaban 10 mg administered 1 day before and 3 days after surgery in morbidly 
obese patients scheduled to undergo bariatric surgery.38 Twelve patients were 
assessed: 6 underwent Roux-en-Y gastric bypass and 6 underwent sleeve gastrectomy. 
The preoperative data revealed area under the plasma concentration-time curve (AUC) 
values in this obese population that were comparable with those reported after 
administration of rivaroxaban 10 mg in healthy volunteers and patients who had 
undergone hip replacement.14,39 A slight increase in AUC was observed after bariatric 
surgery in the overall study population; the difference compared with the preoperative 
measurement was more apparent among patients who underwent sleeve gastrectomy 
than in those who underwent Roux-en-Y gastric bypass (Table 2).38 The plasma 
concentration-time curves before and after surgery were largely superimposable for 
gastric bypass patients, whereas a modest difference in peak rivaroxaban concentration 
was observed postoperatively in the sleeve-gastrectomy group (Figure 5).38 
Nonetheless, the observed differences in pharmacokinetic parameters after bariatric 
surgery were within the expected range of individual variation. The pharmacodynamic 
effects of rivaroxaban, as measured by thrombin-antithrombin complexes, prothrombin 
activation fragments F1+2, and D-dimer concentrations, were consistent with the 
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pharmacokinetic profile (Figure 6).38 These data support the concept that the 
pharmacology of a 10-mg dose of rivaroxaban is not significantly affected by bariatric 
surgery. Additional studies with larger numbers of patients, extended duration of 
therapy, and higher rivaroxaban doses would be helpful for a more detailed 
characterization of the rivaroxaban profile. 
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CLINICAL IMPLICATIONS 
The body of clinical evidence does not suggest that dosing adjustments for 
rivaroxaban are needed for patients with a BMI >40 kg/m2 or weight of >120 kg. High 
weight has not been shown to have a clinically meaningful effect on the pharmacology 
of rivaroxaban, and the efficacy and safety profiles of rivaroxaban in high weight/BMI 
subgroups were consistently similar to those observed in patients with normal 
weight/BMI across large pivotal clinical trials in different indications.  
The recent guidance from the ISTH advocates the measurement of peak and 
trough levels of DOACs in patients with a BMI >40 kg/m2 or weight of >120 kg.6 This 
recommendation is based on the assumption that the pharmacology of DOACs will 
differ between obese and non-obese patients. The evidence presented herein, which 
includes a study specifically examining the effects of weight on pharmacology,12 
population pharmacokinetic modeling in diverse patient populations,14-16 and 
pharmacologic data from morbidly obese patients before and after bariatric surgery,38 
indicates that rivaroxaban’s pharmacologic profile in obese or high-weight patients is 
comparable to that observed in patients with normal weight. Therefore, the routine 
measurement of plasma concentrations does not appear to be necessary for patients 
who receive rivaroxaban. 
Exploring the influence of bariatric surgery on drug exposure is still in early 
stages. Although it is well established that the level of anticoagulation achieved with 
VKA therapy is significantly affected by bariatric surgery, necessitating careful 
monitoring and dose adjustment,31-36 less is known regarding the effects of bariatric 
surgery on the anticoagulant activity of DOACs. For rivaroxaban, the available data 
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suggest that pharmacokinetic and pharmacodynamic effects of a 10-mg dose of 
rivaroxaban are not appreciably altered after bariatric surgery. Further study of 
rivaroxaban, ideally with higher doses, and other DOACs in this patient population is 
warranted. 
In total, the data indicate that dose adjustment is not necessary when 
administering rivaroxaban to patients who are obese or who have undergone bariatric 
surgery. Future research should ensure that these populations are adequately 
represented in clinical trials. Moreover, additional studies are needed to further explore 
the effects of obesity/bariatric surgery on the pharmacologic profiles of anticoagulant 
therapies. 
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FIGURE LEGENDS 
 
Figure 1. Mean rivaroxaban plasma concentration-time curve after administration of a 
single 10-mg oral dose. Each weight group included 12 healthy subjects. Reprinted from 
Kubitza et al (2007).12 
 
Figure 2. Influence of body weight on rivaroxaban-mediated (A) median inhibition of 
factor Xa activity and (B) median prolongation of prothrombin time. Each weight group 
included 12 healthy subjects who received a single oral dose of rivaroxaban 10 mg. 
Reprinted from Kubitza et al (2007).12 
 
Figure 3. Relative efficacy of rivaroxaban in weight and body mass index subgroups in 
large phase 3 clinical trials. Odds/hazard ratios and 95% confidence intervals of the 
primary efficacy endpoint for the comparison of rivaroxaban with enoxaparin (RECORD 
studies),21 warfarin (ROCKET AF),20 or enoxaparin/vitamin K antagonist therapy 
(EINSTEIN studies).28  
 
Figure 4. Relative safety of rivaroxaban in weight and body mass index subgroups in 
large phase 3 clinical trials. Hazard ratios and 95% confidence intervals of the 
composite endpoint of major bleeding and clinically relevant nonmajor bleeding for the 
comparison of rivaroxaban with enoxaparin (RECORD studies),21 warfarin (ROCKET 
AF),20 or enoxaparin/vitamin K antagonist therapy (EINSTEIN studies).28  
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Figure 5. Rivaroxaban plasma concentration-time curve before and after bariatric 
surgery, stratified by procedure type, following administration of single 10-mg oral 
doses. Panel A represents patients who underwent Roux-en-Y gastric bypass (n = 6) 
and panel B represents patients who underwent sleeve gastrectomy (n = 6). Reprinted 
from Kröll D, et al.38 
 
Figure 6. Comparison of pharmacodynamic measures performed following 
administration of rivaroxaban 10 mg before and after bariatric surgery, stratified by 
procedure type. Top panels: thrombin-antithrombin complex concentrations; middle 
panels: prothrombin activation fragment F1+2 concentrations; bottom panels: D-dimer 
concentrations. Data represent medians and ranges for 6 patients who underwent 
Roux-en-Y gastric bypass and 5 patients who underwent sleeve gastrectomy. 
Interpretation of the postoperative results must take into consideration the procoagulant 
state induced by surgical intervention and the administration of low-molecular-weight 
heparin the previous day as part of the postoperative standard of care. Reprinted from 
Kröll D, et al.38 
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TABLES  
Table 1. Characteristics and Weight Category Distributions in Large Phase 3 Clinical Trials With Rivaroxaban 
Study 
Population Treatment 
Weight Category Distribution 
Patients, n (%) 
≤70 kg >70-90 kg >90 kg  
RECORD studies21* 
Patients scheduled for 
elective total hip or knee 
arthroplasty 
Rivaroxaban 10 mg OD 
Enoxaparin 40 mg OD or 30 mg every 12 hours 
2093 (33.9) 
1988 (32.1) 
2669 (43.3) 
2732 (44.1) 
1409 (22.8) 
1474 (23.8) 
 
ROCKET AF20* 
Patients with nonvalvular 
atrial fibrillation at increased 
risk for stroke 
Rivaroxaban 20 mg daily† 
Dose-adjusted warfarin 
2013 (28.4) 
2012 (28.4) 
3031 (42.8) 
3135 (44.2) 
2035 (28.7) 
1942 (27.4) 
 
  ≤50 kg >50-100 kg >100 kg Missing 
EINSTEIN DVT18 
Patients with objectively 
confirmed proximal deep vein 
thrombosis, without 
symptomatic pulmonary 
embolism 
Rivaroxaban 15 mg BID for 3 weeks, then 20 mg OD 
Enoxaparin followed by a VKA 
37 (2.1) 
49 (2.9) 
1443 (83.4) 
1422 (82.8) 
245 (14.2) 
246 (14.3) 
6 (0.3) 
1 (<0.1) 
EINSTEIN PE19 
Patients with acute 
symptomatic pulmonary 
embolism with or without 
deep vein thrombosis 
Rivaroxaban 15 mg BID for 3 weeks, then 20 mg OD 
Enoxaparin followed by a VKA 
38 (1.6) 
43 (1.8) 
2034 (84.1) 
2010 (83.3) 
345 (14.3) 
359 (14.9) 
2 (<0.1) 
1 (<0.1) 
BID, twice daily; OD, once daily; VKA, vitamin K antagonist. 
*Derived from the number of patients included in the subgroup analysis for the primary efficacy endpoint. 
†Rivaroxaban dose was 15 mg daily for patient with a creatinine clearance of 30 to 49 mL per minute. 
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Table 2. Pharmacokinetic Parameters of Rivaroxaban Before and After Bariatric Surgery 
Parameter* Before Surgery After Surgery Ratio† 
All patients pooled 
AUC (µg • h/L) 952.6 / 16.8 1095.5 / 16.8 0.87 [0.77-0.98] 
Cmax (µg/L) 135.9 / 19.3 137.3 / 33.3 0.99 [0.79-1.24] 
t1/2 (h) 13.5 / 38.8 11.6 / 58.7 1.16 [0.82-1.64] 
VZ/f (L/kg) 47.9 / 22.3 44.4 / 26.1 1.08 [0.99-1.18] 
tmax (h) 1.5 (0.9-4) 2 (1-4) NA 
Roux-en-Y gastric bypass 
AUC (µg • h/L) 933.7 / 22.3 1029.4 / 7.4 0.91 [0.75-1.09] 
Cmax (µg/L) 136.5 / 10.7 110.8 / 31.8 1.23 [0.91-1.66] 
t1/2 (h) 13.8 / 46.6 15 / 60.0 0.92 [0.57-1.48] 
VZ/f (L/kg) 55.3 / 22.5 52.7 / 20.8 1.05 [0.91-1.21] 
tmax (h) 1.5 (0.9-4) 2.5 (1-4) NA 
Sleeve gastrectomy 
AUC (µg • h/L) 971.9 / 10.6 1165.8 / 21.9 0.83 [0.68-1.02] 
Cmax (µg/L) 135.3 / 26.7 170.0 / 15.9 0.80 [0.59-1.08] 
t1/2 (h) 13.1 / 34.1 8.9 / 44.6 1.47 [0.82-2.64] 
VZ/f (L/kg) 41.5 / 9.5 37.4 / 18.1 1.11 [0.95-1.29] 
tmax (h) 1.5 (1-4) 1.5 (1-4) NA 
AUC, area under the plasma concentration-time curve from time 0 to infinity; Cmax, peak plasma concentration; t1/2, 
terminal half-life; tmax, time to peak plasma concentration; Vz/f, (Dose/C0)/body weight apparent volume of distribution 
during the terminal phase divided by total body weight (in kg). 
*Data are geometric mean/coefficient of variation, except for tmax, which is presented as median (range).  †Ratio of before/after surgery and 95% confidence interval. 
Reprinted from Kröll D, et al.38 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CLINICAL SIGNIFICANCE 
 
• Recent ISTH guidelines have questioned the use of DOACs in obese patients. 
The recommendation was uniform for the DOAC drug class.  
• Moreover, there are currently no recommendations regarding DOAC usage in 
patients who have undergone bariatric surgery.  
• This review assessed the available evidence for rivaroxaban, and data retrieved 
indicate that its clinical profile is not affected by high body weight or bariatric 
surgery; hence, no dose adjustment is needed. 
 
